Skip to main content
Quest Diagnostics

A New LC-MS/MS Assay for the Quantification of Aβ40 and Aβ42 in Plasma: Validation and Clinical Performance

REDDI Lab Symposium 2023

Clemson, SC, Aug 18, 2023

Poster presentation: A New LC-MS/MS Assay for the Quantification of Aβ40 and Aβ42 in Plasma:Validation and Clinical Performance 

Authors: Weber DM, Kim JC, Goldman SM, Racke MK, Clarke NJ

Specialty: Neurology

Related content

Audio Podcast
Alzheimer’s disease: A new generation of screenings and therapies on the horizon
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings
On-Demand Webinar
The Emerging Role of Blood-based Biomarkers in Alzheimer's Disease
Publication
The small HDL particle hypothesis of Alzheimer's disease
Conference Presentation
A new LC-MS/MS Assay for the Quantification of Aβ40 and Aβ42 in Plasma: Validation and Clinical Performance
Conference Presentation
The AlzMatch Study: remote plasma acquisition to pre-screen for preclinical Alzheimer's disease trials

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.